2022
Overlapping needs for sexual and reproductive health and HIV prevention in women with substance use disorders
Gibson B, Hoff E, Haas A, Adams ZM, Price CR, Goddard-Eckrich D, Sheth SS, Dasgupta A, Meyer JP. Overlapping needs for sexual and reproductive health and HIV prevention in women with substance use disorders. Women's Health 2022, 18: 17455065211070543. PMID: 35023410, PMCID: PMC8771433, DOI: 10.1177/17455065211070543.Peer-Reviewed Original ResearchConceptsSubstance use disordersPre-exposure prophylaxisUse disordersHIV preventionReproductive healthReproductive health service utilizationHigh HIV risk behaviorHealth service utilizationUnique health issuesCross-sectional evaluationHIV risk behaviorsHigh unmet needReproductive health behaviorsReproductive health needsConcurrent clinical trialsForm of contraceptionTime of assessmentPregnancy intentionReproductive ageClinical trialsUnintended pregnancyService utilizationCriminal justice involvementDrug treatmentContraceptive use
2021
Effectiveness of HPV vaccine by age at vaccination and number of doses: protocol for a population-based matched case–control study
Oliveira CR, Ortiz AM, Sheth SS, Shapiro ED, Niccolai LM. Effectiveness of HPV vaccine by age at vaccination and number of doses: protocol for a population-based matched case–control study. BMJ Open 2021, 11: e043093. PMID: 33875441, PMCID: PMC8057558, DOI: 10.1136/bmjopen-2020-043093.Peer-Reviewed Case Reports and Technical NotesConceptsHigh-grade cervical lesionsPre-licensure clinical trialsHPV vaccineCase-control studyNumber of dosesClinical trialsFirst human papillomavirus (HPV) vaccineMultivariate conditional logistic regressionNormal Pap test resultsReal-world clinical settingHuman papillomavirus vaccinePap test resultsHPV types 16Time of immunisationReal-world effectivenessConditional logistic regressionInstitutional review boardDate of testingPapillomavirus vaccineCervical lesionsPotential confoundersVaccine programMedical recordsPersistent infectionType 16